Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2023 Jun 08
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-PSMA-617 Radionuclide Therapy.
Related Questions
When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?
2
1 Answers
Mednet Member
Radiation Oncology
One important consideration in the recommendation of Lu-177-PSMA radiopharmaceutical therapy (RPT) is an assessment of a patient’s marrow reserve, as hematologic toxicity is one of the most common clinically relevant toxicities after such treatment. Important clinical features to help assess the lik...
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
3
2 AnswersMednet Member
Radiation Oncology · Corewell Health
For the most part, no. Not unless you're a big academic medical center with a robust multidisciplinary team willing to tackle the significant logistical challenges associated with this scenario.I'm aware of no literature in this scenario specifically for Pluvicto, but we can look at the radiopharmac...